Vir Biotechnology, Inc. has entered into an exclusive worldwide license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases, acquired by Sanofi from Amunix Pharmaceuticals. Sanofi will receive an upfront payment and is eligible to receive future development, regulatory and commercial milestone payments and royalties on sales.    Vir also announced a strategic restructuring...